Skip to main content
HealthReportedMedium
5.1

FDA rejects Capricor's Duchenne cell therapy after lengthy review

The FDA has rejected Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy, a decision that had been anticipated given the prolonged review. The rejection is a setback for the company and for patients awaiting a new treatment option, though the specific reasons for the refusal have not been detailed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

STAT Newsabout 18 hours agoUSengCredibility 19%View source

Score Breakdown

Mosaic Score5.1
Model confidence0.9
Significance0.5
Source credibility0.2

Intelligence Tags

Entities

United Statescountry
Source

Related signals

8 found